These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3287456)

  • 1. Protective effects of CG-4203, a novel stable prostacyclin analog, in traumatic shock.
    Bitterman H; Stahl GL; Lefer AM
    Prostaglandins; 1988 Jan; 35(1):41-50. PubMed ID: 3287456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-shock properties of the prostacyclin analog, iloprost, in traumatic shock.
    Levitt MA; Lefer AM
    Prostaglandins Leukot Med; 1986 Dec; 25(2-3):175-85. PubMed ID: 2434958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salutary effects of CG-4203, a novel, stable prostacyclin analog, in hemorrhagic shock.
    Bitterman H; Smith BA; Lefer DJ; Lefer AM
    J Cardiovasc Pharmacol; 1988 Sep; 12(3):293-9. PubMed ID: 2464101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock.
    Bitterman H; Smith BA; Lefer AM
    Arzneimittelforschung; 1988 Oct; 38(10):1389-93. PubMed ID: 3196378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial actions of prostacyclin in traumatic shock.
    Lefer AM; Sollott SL; Galvin MJ
    Prostaglandins; 1979 May; 17(5):761-7. PubMed ID: 386429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of prostaglandin E1 infusion in experimental traumatic shock.
    Levitt MA; Lefer AM
    Crit Care Med; 1987 Aug; 15(8):769-73. PubMed ID: 3608533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock.
    Stahl GL; Bitterman H; Lefer AM
    Thromb Res; 1989 Feb; 53(3):327-38. PubMed ID: 2718150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a combination thromboxane receptor antagonist and lipoxygenase inhibitor in traumatic shock.
    Levitt MA; Stahl G; Lefer AM
    Resuscitation; 1988 Jul; 16(3):211-20. PubMed ID: 2845544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of a new LTD4 antagonist (LY-171883) in traumatic shock.
    Hock CE; Lefer AM
    Circ Shock; 1985; 17(4):263-72. PubMed ID: 3841503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial actions of BN 50739, a new PAF receptor antagonist, in murine traumatic shock.
    Karasawa A; Rochester JA; Lefer AM
    Methods Find Exp Clin Pharmacol; 1990 May; 12(4):231-7. PubMed ID: 2165204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of two leukotriene antagonists in rat traumatic shock.
    Levitt MA; Lefer AM
    Methods Find Exp Clin Pharmacol; 1987 May; 9(5):269-73. PubMed ID: 3613754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
    Bitterman H; Phillips GR; Dragon G; Lefer AM
    J Pharmacol Exp Ther; 1987 Jul; 242(1):8-14. PubMed ID: 3039116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mechanism of action of a prostacyclin enhancing agent in haemorrhagic shock.
    Bitterman H; Lefer DJ; Lefer AM
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Jun; 337(6):679-86. PubMed ID: 3063971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action of PGE1 in hemorrhagic shock in rats.
    Bitterman H; Stahl GL; Terashita Z; Lefer AM
    Ann Emerg Med; 1988 May; 17(5):457-62. PubMed ID: 3364825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock.
    Aoki N; Johnson G; Siegfried MR; Lefer AM
    Eicosanoids; 1989; 2(3):169-74. PubMed ID: 2534278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of a novel nonglucocorticoid 21-aminosteroid (U74006F) during traumatic shock in rats.
    Aoki N; Lefer AM
    J Cardiovasc Pharmacol; 1990 Feb; 15(2):205-10. PubMed ID: 1689414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of a platelet activating factor (PAF) antagonist and its combined treatment with prostaglandin (PG) E1 in traumatic shock.
    Terashita Z; Stahl GL; Lefer AM
    J Cardiovasc Pharmacol; 1988; 12(5):505-11. PubMed ID: 2468048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salutary consequences of blockade of platelet activating factor in hemorrhagic shock.
    Stahl GL; Bitterman H; Terashita Z; Lefer AM
    Eur J Pharmacol; 1988 May; 149(3):233-40. PubMed ID: 3409951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial actions of antagonism of peptide leukotrienes in hemorrhagic shock.
    Bitterman H; Smith BA; Lefer AM
    Circ Shock; 1988 Mar; 24(3):159-68. PubMed ID: 3383353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of a neutral protease inhibitor in traumatic shock.
    Hock CE; Lefer AM
    Pharmacol Res Commun; 1985 Mar; 17(3):217-26. PubMed ID: 4011646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.